ALLARITY THERAPEUTICS
Allarity Therapeutics is a biopharmaceutical company that develops oncology products and drugs for the personalized treatment of cancer. The company utilizes drug response predictor technology to refine patient selection and improve clinical outcomes. Its product pipeline includes Dovitinib, a pan-tyrosine kinase inhibitor for renal cell carcinoma (RCC), Stenoparib (2X-121), a dual PARP inhibitor, and Tankyrase Inhibitor for ovarian cancer; IXEMPRA (Ixabepilone), a microtubulin inhibitor for metastatic breast cancer.
ALLARITY THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Oncology Pharmaceutical
Founded:
2004-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.allarity.com
Total Employee:
11+
Status:
Active
Contact:
401-426-4664
Email Addresses:
[email protected]
Total Funding:
18.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Repligen
Repligen is a biopharmaceutical company developing consumable products for the manufacture of biological drugs.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
Official Site Inspections
http://www.allarity.com Semrush global rank: 4.95 M Semrush visits lastest month: 1.71 K
- Host name: 104.21.18.18
- IP address: 104.21.18.18
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Allarity Therapeutics"
Allarity Therapeutics Outlines Company’s 2024 Progress and …
Jul 22, 2024 Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows …See details»
Allarity Therapeutics, Inc. (ALLR) - Yahoo Finance
Find the latest Allarity Therapeutics, Inc. (ALLR) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Allarity Therapeutics - Crunchbase Company Profile & Funding
Organization. Allarity Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Allarity Therapeutics is a …See details»
2020 in Review: A Letter from Allarity’s CEO
Dec 18, 2020 Smerud is a leading European-based clinical contract research organization (CRO) with expertise in the development of precision cancer drugs, and Smerud has …See details»
Allarity Therapeutics Outlines Company’s 2024 Progress and
Jul 22, 2024 About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer …See details»
Allarity Therapeutics - LinkedIn
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers.See details»
Allarity Therapeutics Makes Strategic Pivot to Focus Solely
Mar 27, 2024 Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused …See details»
Allarity Therapeutics Strengthens Leadership with Key ... - Nasdaq
Oct 3, 2024 About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. …See details»
Allarity Therapeutics Inc, ALLR:NAQ profile - FT.com - Financial Times
Nov 8, 2024 Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of …See details»
Allarity Therapeutics Outlines Company’s 2024 Progress and …
Jul 22, 2024 New Strong Cash Balance: Allarity Therapeutics is pleased to announce that the Company now has a financial runway extending into 2026 at its current burn rate with a cash …See details»
Allarity Therapeutics, Inc. (ALLR) - Yahoo Finance Canada
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug …See details»
Allarity Therapeutics Strengthens Board of Directors with …
BOSTON (July 24, 2023) — Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific …See details»
Allarity Therapeutics Outlines Company’s 2024 ... - Markets Insider
Jul 22, 2024 Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more …See details»
Allarity Therapeutics Strengthens Leadership with Key …
Oct 3, 2024 In his new role at Allarity, Dr. Graff will continue to oversee the Company’s clinical development programs, including the advancement of its dual PARP and Tankyrase inhibitor, …See details»
ALLR Stock Price Quote | Morningstar
Nov 25, 2024 Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with …See details»
Allarity Therapeutics A/S
Allarity Therapeutics Inc.’s Form S-4 Registration Statement effective. • On November 5, the Company published a notice of an extraordinary general meeting to be held on November 22, …See details»
Allarity Therapeutics Closes Its Recapitalization, Share
Dec 21, 2021 Press release Cambridge, MA U.S.A. (December 21, 2021) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company …See details»
Allarity Therapeutics, Inc. (ALLR) - Stock Analysis
Nov 21, 2024 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by …See details»
Allarity Encourages Shareholders to Vote FOR the Reverse Stock …
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized …See details»